(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 February 2015 (19.02.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/022658 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 21/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/IB2014/063904

(22) International Filing Date:
13 August 2014 (13.08.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/865,861 14 August 2013 (14.08.2013) US
61/983,567 24 April 2014 (24.04.2014) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(71) Applicants *(for US only)*: **PAPANICOLAOU, Dimitris** [US/US]; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **ROUBENOFF, Ronenn** [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 220 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **TSENG, Brian** [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 220 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **GUBSER, Charles** [US/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **GLASS, David** [US/US]; c/o Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) Agent: **DIDELON, Frederic**; Novartis Pharma AG, Patent Department, CH-4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
28 May 2015

(54) Title: METHODS OF TREATING SPORADIC INCLUSION BODY MYOSITIS

(57) Abstract: The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.

WO 2015/022658 A3